NEW DELHI- A panel of drug regulatory organisation Central Drugs Standard Control Organisation (CDSCO) recommended permitting the Phase 1 clinical trials of Bharat Biotech’s intranasal COVID-19 vaccine. Government of India has termed it as a ‘game changer’ in fighting the COVID-19 pandemic.
Officials said that just one drop in each nostril is enough for protection against the COVID-19 infection and there is no need for a trained healthcare worker to administer the dose. It also eliminates the needle related risks and is completely suitable for children and adults. Bharat Biotech has sought the permission from Drug Controller General of India (DCGI) to conduct the Phase 1 and Phase 2 clinical trials of this vaccine. It was referred to an expert committee of CDSCO, which on Tuesday, January 19, recommended granting the permission for trials.
Krishna Ella, Chairman, Bharat Biotech, earlier said that the drug manufacturer is focusing on the development of an intranasal vaccine as the present vaccines are administered in two doses which is a huge task in a country like India. She also added that the country will need at least 2.6 billion syringes and needles which will further add to the waste and pollution.